Examination of the Oxidative Stress-Related Parameters with Methotrexate-Induced Albino Wistar Rats

In 1940s a specific antagonist for folic acid is developed for first time known as Methotrexate which inhibits the proliferation of malignant cells basically byinhibiting the de novo synthesis of purines and pyrimidines. The presented study concludes that the acute exposure to Methotrexate produced no appreciable changes but in routine consultation of oxidative stress parameters including the glutathione metabolizing system in patients using long term MTX cure can be considered. 

Methotrexate is a folic acid antagonist, widely used as a chemotherapeutic agent in the treatment of various cancerous stages (leukaemia, lymphoma, osteosarcoma, head and neck tumours, lung cancer, breast cancer, etc.) and in the treatment of various inflammatory diseases. It is also used for the treatment of multiple sclerosis,dermatomyositis, sarcoidosis, psoriasis, and rheumatoid arthritis, disorders causing inflammation. Its side effects include hypersensitivity pneumonia, central and peripheral nervous system toxicity, liver and gastrointestinal system dysfunctions and hematologic failure.